I_CD
kappa_NN
B\/MAD_NN
-3_CD
masks_VBZ
the_DT
nuclear_JJ
localization_NN
signal_NN
of_IN
NF-kappa_NN
B_NN
p65_NN
and_CC
requires_VBZ
the_DT
transactivation_NN
domain_NN
to_TO
inhibit_VB
NF-kappa_NN
B_NN
p65_NN
DNA_NN
binding_NN
._.

The_DT
active_JJ
nuclear_JJ
form_NN
of_IN
the_DT
NF-kappa_NN
B_NN
transcription_NN
factor_NN
complex_NN
is_VBZ
composed_VBN
of_IN
two_CD
DNA_NN
binding_NN
subunits_NNS
,_,
NF-kappa_NN
B_NN
p65_NN
and_CC
NF-kappa_NN
B_NN
p50_NN
,_,
both_DT
of_IN
which_WDT
share_VBP
extensive_JJ
N-terminal_JJ
sequence_NN
homology_NN
with_IN
the_DT
v-rel_NN
oncogene_NN
product_NN
._.

The_DT
NF-kappa_NN
B_NN
p65_NN
subunit_NN
provides_VBZ
the_DT
transactivation_NN
activity_NN
in_IN
this_DT
complex_NN
and_CC
serves_VBZ
as_IN
an_DT
intracellular_JJ
receptor_NN
for_IN
a_DT
cytoplasmic_JJ
inhibitor_NN
of_IN
NF-kappa_NN
B_NN
,_,
termed_VBN
I_NN
kappa_NN
B_NN
._.

In_IN
contrast_NN
,_,
NF-kappa_NN
B_NN
p50_NN
alone_RB
fails_VBZ
to_TO
stimulate_VB
kappa_NN
B-directed_JJ
transcription_NN
,_,
and_CC
based_VBN
on_IN
prior_JJ
in_FW
vitro_FW
studies_NNS
,_,
is_VBZ
not_RB
directly_RB
regulated_VBN
by_IN
I_NN
kappa_NN
B_NN
._.

To_TO
investigate_VB
the_DT
molecular_JJ
basis_NN
for_IN
the_DT
critical_JJ
regulatory_JJ
interaction_NN
between_IN
NF-kappa_NN
B_NN
and_CC
I_NN
kappa_NN
B\/MAD_NN
-3_CD
,_,
a_DT
series_NN
of_IN
human_JJ
NF-kappa_NN
B_NN
p65_NN
mutants_NNS
was_VBD
identified_VBN
that_IN
functionally_RB
segregated_VBD
DNA_NN
binding_NN
,_,
I_NN
kappa_NN
B-mediated_JJ
inhibition_NN
,_,
and_CC
I_NN
kappa_NN
B-induced_JJ
nuclear_JJ
exclusion_NN
of_IN
this_DT
transcription_NN
factor_NN
._.

Results_NNS
from_IN
in_FW
vivo_FW
expression_NN
studies_NNS
performed_VBD
with_IN
these_DT
NF-kappa_NN
B_NN
p65_NN
mutants_NNS
revealed_VBD
the_DT
following_NN
:_:
1_LS
-RRB-_-RRB-
I_NN
kappa_NN
B\/MAD_NN
-3_CD
completely_RB
inhibits_VBZ
NF-kappa_NN
B_NN
p65-dependent_JJ
transcriptional_JJ
activation_NN
mediated_VBN
through_IN
the_DT
human_JJ
immunodeficiency_NN
virus_NN
type_NN
1_CD
kappa_NN
B_NN
enhancer_NN
in_IN
human_JJ
T_NN
lymphocytes_NNS
,_,
2_LS
-RRB-_-RRB-
the_DT
binding_NN
of_IN
I_NN
kappa_NN
B\/MAD_NN
-3_CD
to_TO
NF-kappa_NN
B_NN
p65_NN
is_VBZ
sufficient_JJ
to_TO
retarget_VB
NF-kappa_NN
B_NN
p65_NN
from_IN
the_DT
nucleus_NN
to_TO
the_DT
cytoplasm_NN
,_,
3_LS
-RRB-_-RRB-
selective_JJ
deletion_NN
of_IN
the_DT
functional_JJ
nuclear_JJ
localization_NN
signal_NN
present_JJ
in_IN
the_DT
Rel_NN
homology_NN
domain_NN
of_IN
NF-kappa_NN
B_NN
p65_NN
disrupts_VBZ
its_PRP$
ability_NN
to_TO
engage_VB
I_CD
kappa_NN
B\/MAD_NN
-3_CD
,_,
and_CC
4_LS
-RRB-_-RRB-
the_DT
unique_JJ
C-terminus_NN
of_IN
NF-kappa_NN
B_NN
p65_NN
attenuates_VBZ
its_PRP$
own_JJ
nuclear_JJ
localization_NN
and_CC
contains_VBZ
sequences_NNS
that_WDT
are_VBP
required_VBN
for_IN
I_NN
kappa_NN
B-mediated_JJ
inhibition_NN
of_IN
NF-kappa_NN
B_NN
p65_NN
DNA_NN
binding_NN
activity_NN
._.

Together_RB
,_,
these_DT
findings_NNS
suggest_VBP
that_IN
the_DT
nuclear_JJ
localization_NN
signal_NN
and_CC
transactivation_NN
domain_NN
of_IN
NF-kappa_NN
B_NN
p65_NN
constitute_VBP
a_DT
bipartite_JJ
system_NN
that_WDT
is_VBZ
critically_RB
involved_VBN
in_IN
the_DT
inhibitory_JJ
function_NN
of_IN
I_NN
kappa_NN
B\/MAD_NN
-3_CD
._.

Unexpectedly_RB
,_,
our_PRP$
in_FW
vivo_FW
studies_NNS
also_RB
demonstrate_VBP
that_IN
I_CD
kappa_NN
B\/MAD_NN
-3_CD
binds_VBZ
directly_RB
to_TO
NF-kappa_NN
B_NN
p50_NN
._.

This_DT
interaction_NN
is_VBZ
functional_JJ
as_IN
it_PRP
leads_VBZ
to_TO
retargeting_NN
of_IN
NF-kappa_NN
B_NN
p50_NN
from_IN
the_DT
nucleus_NN
to_TO
the_DT
cytoplasm_NN
._.

However_RB
,_,
no_DT
loss_NN
of_IN
DNA_NN
binding_NN
activity_NN
is_VBZ
observed_VBN
,_,
presumably_RB
reflecting_VBG
the_DT
unique_JJ
C-terminal_JJ
domain_NN
that_WDT
is_VBZ
distinct_JJ
from_IN
that_IN
present_JJ
in_IN
NF-kappa_NN
B_NN
p65_NN
._.

